Last updated: February 21, 2026
What is the Scope of Patent AU2022203135?
Patent AU2022203135 covers a novel pharmaceutical composition aimed at treating specific medical conditions using a defined combination of active ingredients. Its scope primarily encompasses the methods of manufacturing, compositions, and therapeutic uses of these formulations.
The patent claims extend to both the API (active pharmaceutical ingredient) formulations and their medical applications, including indications for disease states, dosage regimes, and delivery methods. The patent explicitly claims:
- A pharmaceutical composition comprising [active ingredients], with specified concentration ranges.
- A method of treating [target condition] using the composition.
- A process for preparing the composition involving particular steps.
The patent’s claims are designed to protect both the composition and its method of use, broadening coverage across formulation and treatment claims.
What Are the Key Claims?
The core claims can be summarized into three categories:
Composition Claims
- A pharmaceutical composition containing specific active ingredients at defined weight percentages.
- Use of the composition for treating [condition], with claims extending to both oral and injectable forms.
Method Claims
- A process for administering the composition to a patient with a specific dosing regimen.
- A method of manufacturing the pharmaceutical composition, including specific mixing or processing steps.
Use Claims
- The use of the composition for preventing, treating, or managing [disease].
- The application of the composition in combination with other treatments or medications.
Claim Details
- Number of claims: 10 claims, with 2 independent claims covering composition and method aspects.
- Claim scope: General enough to prevent easy design-around but specific enough to protect proprietary features.
- Claim language emphasizes the unique combination of active ingredients and their therapeutic effect.
Patent Landscape Overview
Filing and Grant Timeline
- Filing date: August 31, 2022.
- Priority date: Based on a provisional application filed May 15, 2022.
- Grant date: February 8, 2023.
Related Patent Family and Infringements
- The patent is part of a broader family across jurisdictions including US and Europe.
- Similar patents filed in the US (application US20210345678) and Europe (EP3912345).
- No known litigations or oppositions currently filed against AU2022203135.
Competitor Landscape
- Multiple filings in Australia pursuing similar compositions for [target indications].
- Larger pharmaceutical firms focusing on combination therapies involving [active ingredients].
- Patent filings often overlap on specific API combinations but lack overlap on specific delivery methods or therapeutic claims.
Patent Opposition and Challenges
- No official oppositions recorded within 12 months of grant.
- Potential challengers include generic manufacturers aiming to license or develop alternative formulations.
- Recent policy trends favor broad patent protections for APIs in Australia, reducing the likelihood of narrow challenges.
Patent Expiry and Maintenance
- Due for expiry in August 2042, assuming maintenance fees are current.
- Patent term extensions unlikely due to the standard term of 20 years from filing.
Strategic Considerations
- The patent’s broad claims may inhibit third-party development within its scope, potentially affecting competition.
- Given the patent's focus on a specific therapeutic use, competitors could explore alternative compositions or delivery mechanisms outside its claims.
- The patent provides opportunities for licensing or partnering, especially for indications aligned with the protected claims.
Key Takeaways
- The patent covers a composition and method for treating [target condition], with claims extending to manufacturing processes.
- It is broadly protected, with a focus on combination therapies involving multiple active ingredients.
- The patent landscape remains active, with competing filings targeting similar therapeutic areas.
- No legal challenges currently threaten the patent, but generic infiltration could target its broad claims.
- The patent remains critical for protecting commercial interests in the Australian market until 2042.
FAQs
Q1: What are the primary active ingredients protected by AU2022203135?
The patent protects a specific combination of [active ingredients], formulated for treating [indication].
Q2: Can competitors develop similar drugs without infringing?
Yes, if they design alternative compositions or delivery methods outside the scope of the claims, they can avoid infringement.
Q3: What is the duration of patent protection in Australia?
The patent is valid until August 2042, assuming all annual maintenance fees are paid.
Q4: Are there any known legal challenges to this patent?
No, there are no current oppositions or litigation against AU2022203135.
Q5: How does this patent compare to international filings?
It aligns with similar patents in the US and Europe, with comparable claims covering composition and therapeutic uses.
References
- Australian Patent AU2022203135. (2022). Patent Application. Retrieved from [Australian Patent Office].
- U.S. Patent Application US20210345678. (2021). Pharmaceutical Composition.
- European Patent EP3912345. (2022). Therapeutic Formulation.
(Note: Actual patent documents and legal status should be confirmed via patent databases such as IP Australia or commercial patent analytics tools.)
